PTSD, Negative and Positive Emotion Dysfunction and Substance USE in IPV Victims
IPV 受害者的 PTSD、消极和积极情绪功能障碍以及药物使用
基本信息
- 批准号:9920685
- 负责人:
- 金额:$ 13.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-07-01 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdvanced DevelopmentAffectAlcohol consumptionAlcohol or Other Drugs useAreaArousalBehaviorBehavior assessmentBehavioralChronicClinical SciencesColoradoCommunitiesConnecticutCuesDataData ReportingDevelopmentDrug usageEgoEmotionsEnvironmentEthicsEvidence based treatmentExhibitsExposure toFunctional disorderFundingGoalsHIVHIV SeropositivityHealthHealthcareIndividualInstitutesInterventionLiteratureMaintenanceManuscriptsMeasuresMediatingMediationMedicalMentored Patient-Oriented Research Career Development AwardMentorsMethodologyMethodsModelingNational Institute of Drug AbuseNeurosecretory SystemsOutcomePathogenesisPathologyPatient Self-ReportPhysiologicalPopulationPost-Traumatic Stress DisordersPostdoctoral FellowPrevalencePreventionPrevention ResearchPreventive InterventionProcessPsychiatryPublic HealthPublishingRecurrenceReportingResearchResearch DesignResourcesRiskRisk BehaviorsRisk-TakingRoleSafetySamplingSeveritiesSexual PartnersStimulusStrategic PlanningSymptomsSystemTestingTimeTobacco useTrainingTranslational ResearchTraumaUnited States National Institutes of HealthUniversitiesUnsafe SexVeteransVictimizationWomanalcohol misusealternative treatmentassociated symptombasecareerclinically relevantdesigndrug misuseemotion regulationemotional experienceexperiencehigh riskhigh risk populationhypothalamic-pituitary-adrenal axisimplementation strategyindexinginnovationinterestintimate partner violenceintravenous drug usermedical schoolsmultidisciplinarynovelpositive emotional statepreventprogramspsychologicreduced substance useresponsesexsexual risk behaviorskillsstemsubstance abuse preventiontheoriestobacco smokerstrauma exposureviolence exposurevirtual
项目摘要
PROJECT SUMMARY/ABSTRACT
IPV is a pervasive and serious public health issue, affecting nearly one in three women nationally in
their lifetime. IPV-exposed women have rates of drug and alcohol misuse that are 2–7 times higher than
women nationally. As many as 70% are tobacco smokers. [IPV-exposed women have sex with more risky
partners, including those who are HIV-positive, IV drug users, and nonmomgomous, and are more likely to
engage in unprotected sex and trade sex, and report more sex partners.] PTSD is highly prevalent among
IPV-exposed women (31 to 84%), and IPV-related PTSD symptoms are positively associated with drug,
alcohol, and tobacco use and HIV/sexual risk. Despite the clear clinical relevance of PTSD in this
population, particularly with regard to substance use and risky sex, no studies have explicated mechanisms
that may account for relations between PTSD symptoms and substance use and HIV/sexual risk behaviors
among IPV-exposed women. Emotion dysfunction has been identified as a key mechanism in the pathogenesis
of a wide range of psychological difficulties and maladaptive behaviors, including PTSD, substance use,
and HIV/sexual risk. Yet, research on mechanisms underlying these health outcomes generally, and the
potential mechanism of emotion dysfunction in particular, is absent in this population. IPV-exposed women
constitute a unique population distinct from other trauma-exposed populations. IPV is chronic; women are
recurrently victimized by their partners and repeatedly exposed to potentially traumatic stimuli in their
environment. This unique context poses increased risk for PTSD symptoms, emotion dysfunction,
substance use, and HIV/sexual risk. Existing intervention models for treating PTSD and co-occurring
substance use and/or risky sex (e.g., Seeking Safety, Project Connect) were not developed for women who
remain in unsafe situations, are seldom community-based, and do not have an integrated focus on IPV, PTSD,
substance use, and HIV/sexual risk. Consistent with current initiatives (e.g., NIH strategic plans), identifying
mechanistic processes, across multiple systems (i.e., physiological and behavioral), underlying the relations
among PTSD, substance use, and HIV/sexual risk in this population is a critical first step in developing
targeted interventions that are safe for IPV-exposed women in the community. The proposed study
addresses such critical gaps in the research with an innovative, context-specific, multi-method approach
among 150 women currently experiencing IPV and using substances. Findings will [identify relations among
physical, sexual, and psychological IPV and emotion dysfunction;] explicate the role of emotion dysfunction in
PTSD symptoms and risk-taking propensity in the lab and substance use and HIV/sexual risk in the real-world;
and test the convergent validity of lab and real-world data. The role of emotion dysfunction in PTSD symptoms
and risk-taking propensity will be measured in the lab via a novel experimental paradigm and in the real world
via daily assessments (i.e., experience sampling).
Dr. Weiss is extremely well-qualified for the Mentored Patient-oriented Research Career Development
Award from the National Institutes of Health. She is a highly productive NIDA-funded T32 Post-doctoral
Fellow in Substance Abuse Prevention Research in the Department of Psychiatry at the Yale University School
of Medicine. During the proposed training period, Dr. Weiss will be housed within the Department of
Psychiatry at the Yale University School of Medicine. She will also draw from the rich resources provided
through the Institute for Clinical and Translational Science at the University of Connecticut Health Center and
the University of Colorado Denver Anschutz Medical Campus. Across these settings, she will have access to
world-class expertise in research design, methodology, and analysis. Dr. Weiss' program of research focuses on
the role of emotion dysfunction in posttraumatic stress disorder (PTSD) and related substance use and
HIV/sexual risk. She has published [12] first-author and [8] co-author manuscripts on these topics. Her long-
term goals are to be a leader in research aimed at preventing and reducing substance use and HIV/sexual risk
among women with PTSD who experience intimate partner violence (IPV); to build strong multi-disciplinary
partnerships to identify potential physiological mechanisms and behavioral processes underlying substance use
and HIV/sexual risk among IPV-exposed women with PTSD; and to develop prevention and intervention
efforts targeting substance use and HIV/sexual risk among IPV-exposed women with PTSD. Continued
sponsorship, mentoring, and directed study will facilitate the development of advanced research skills so Dr.
Weiss can be at the forefront of cutting-edge research in these areas. Short-term career objectives focus on the
development of proficiency in (a) physiological (i.e., sympathetic, parasympathetic, and neuroendocrine) and
behavioral assessments of negative and positive emotion dysfunction; (b) micro-longitudinal research design,
methods, and analysis; and (c) [optimal design and implementation strategies, such as ethical and safety
issues, pertinent to the conduct of research with women who experience IPV and use substances.]
项目摘要/摘要
IPV是一个普遍而严重的公共卫生问题,影响着全国近三分之一的妇女
他们的一生。接触IPV的女性滥用药物和酒精的比率比
全国的女性。多达70%的人是吸烟者。接触IPV的女性与风险更高的人发生性关系
性伴侣,包括艾滋病毒阳性者、静脉吸毒者和非性别者,他们更有可能
进行无保护措施的性行为和性交易,并报告更多的性伴侣。]创伤后应激障碍在
接触IPV的妇女(31%至84%),与IPV相关的创伤后应激障碍症状与药物呈正相关,
酒精、烟草使用和艾滋病毒/性风险。尽管创伤后应激障碍在这方面有明显的临床相关性
人口,特别是在物质使用和危险性行为方面,没有任何研究阐明其机制
这可能解释了创伤后应激障碍症状和药物使用以及艾滋病毒/性危险行为之间的关系。
在接触过IPV的女性中。情绪障碍被认为是其发病的关键机制之一。
广泛的心理困难和适应不良行为,包括创伤后应激障碍,药物使用,
和艾滋病毒/性风险。然而,对这些健康结果背后的机制的研究总体上来说,以及
尤其是情绪障碍的潜在机制,在这一人群中缺失。接触IPV的妇女
构成有别于其他创伤暴露人群的独特人群。IPV是慢性的;女性是
反复受到伴侣的伤害,并反复暴露于潜在的创伤刺激中
环境。这一独特的背景增加了创伤后应激障碍症状、情绪障碍、
物质使用和艾滋病毒/性风险。治疗创伤后应激障碍及其伴发疾病的现有干预模式
物质使用和/或危险的性行为(例如,寻求安全、项目连接)不是为以下女性开发的
仍然处于不安全的情况下,很少以社区为基础,并且没有综合关注IPV、创伤后应激障碍、
物质使用和艾滋病毒/性风险。与当前的倡议(例如,国家卫生研究院战略计划)保持一致,确定
跨多个系统(即,生理和行为)的机械性过程,构成关系的基础
在创伤后应激障碍中,药物使用和艾滋病毒/性风险是发展的关键的第一步
对社区感染IPV的妇女安全的有针对性的干预措施。建议进行的研究
用创新的、针对具体情况的、多方法的方法解决研究中的这些关键差距
在目前正在经历IPV和使用药物的150名妇女中。调查结果将[确定以下各项之间的关系
生理、性和心理IPV和情绪功能障碍;]阐述情绪功能障碍在
创伤后应激障碍症状和实验室中的冒险倾向,以及现实世界中的药物使用和艾滋病毒/性风险;
并对实验室数据和实际数据的收敛有效性进行了检验。情绪障碍在创伤后应激障碍症状中的作用
冒险倾向将通过一种新的实验范式在实验室和现实世界中进行测量
通过日常评估(即经验抽样)。
Weiss博士非常适合指导以患者为导向的研究事业发展
由美国国立卫生研究院颁发的奖项。她是一位由NIDA资助的高效的T32博士后
耶鲁大学精神病学系药物滥用预防研究研究员
医学部。在拟议的培训期间,韦斯博士将被安置在
耶鲁大学医学院的精神病学。她还将利用所提供的丰富资源
通过康涅狄格大学卫生中心的临床和翻译科学研究所
科罗拉多大学丹佛安舒茨医学院。在这些设置中,她将可以访问
在研究设计、方法和分析方面拥有世界级的专业知识。韦斯博士的研究计划侧重于
情绪障碍在创伤后应激障碍(PTSD)及相关物质使用中的作用
艾滋病毒/性风险。她发表了关于这些主题的[12]第一作者和[8]合著者手稿。她长长的-
任期目标是成为旨在预防和减少药物使用和艾滋病毒/性风险的研究的领导者
在经历过亲密伴侣暴力(IPV)的创伤后应激障碍女性中;建立强大的多学科
伙伴关系,以确定潜在的生理机制和潜在的物质使用行为过程
和感染IPV的患有创伤后应激障碍的妇女的艾滋病毒/性风险;并制定预防和干预措施
针对患有创伤后应激障碍的暴露于IPV的妇女的药物使用和艾滋病毒/性风险的努力。续
赞助、指导和定向研究将促进高级研究技能的发展。
韦斯可以走在这些领域的前沿研究的前沿。短期职业目标侧重于
精通(A)生理学(即交感、副交感和神经内分泌)和
消极和积极情绪障碍的行为评估;(B)微观纵向研究设计,
方法和分析;以及(C)[最佳设计和实施战略,例如道德和安全
与对经历IPV和使用药物的妇女进行研究有关的问题。]
项目成果
期刊论文数量(42)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Latent-level relations between DSM-5 PTSD symptom clusters and problematic smartphone use.
- DOI:10.1016/j.chb.2017.02.051
- 发表时间:2017-07
- 期刊:
- 影响因子:9.9
- 作者:Contractor AA;Frankfurt SB;Weiss NH;Elhai JD
- 通讯作者:Elhai JD
Daily relationship between positive affect and drinking to cope: the moderating role of difficulties regulating positive emotions.
- DOI:10.1080/00952990.2018.1508470
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:Weiss NH;Risi MM;Bold KW;Sullivan TP;Dixon-Gordon KL
- 通讯作者:Dixon-Gordon KL
Confirmatory validation of the factor structure and psychometric properties of the Difficulties in Emotion Regulation Scale-Positive.
积极情绪调节量表困难的因素结构和心理测量特性的验证。
- DOI:10.1002/jclp.22768
- 发表时间:2019
- 期刊:
- 影响因子:3
- 作者:Weiss,NicoleH;Darosh,AngelaG;Contractor,AtekaA;Schick,MelissaM;Dixon-Gordon,KatherineL
- 通讯作者:Dixon-Gordon,KatherineL
Clusters of Trauma Types as Measured by the Life Events Checklist for DSM-5.
- DOI:10.1037/str0000179
- 发表时间:2020-11
- 期刊:
- 影响因子:4
- 作者:Contractor AA;Weiss NH;Natesan P;Elhai JD
- 通讯作者:Elhai JD
Difficulties Regulating Positive Emotions and Substance Misuse: The Influence of Sociodemographic Factors.
调节积极情绪和药物滥用的困难:社会人口因素的影响。
- DOI:10.1080/10826084.2020.1729205
- 发表时间:2020
- 期刊:
- 影响因子:2
- 作者:Schick,MelissaR;Weiss,NicoleH;Contractor,AtekaC;Thomas,EmmanuelD;Spillane,NicheaS
- 通讯作者:Spillane,NicheaS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nicole Holland Weiss其他文献
Nicole Holland Weiss的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nicole Holland Weiss', 18)}}的其他基金
Idiographic Examination of Alcohol to Dampen Positive Emotions for Co-morbid Alcohol Use and PTSD
酒精的具体检查可抑制共病酒精使用和创伤后应激障碍的积极情绪
- 批准号:
10730599 - 财政年份:2023
- 资助金额:
$ 13.5万 - 项目类别:
Prediction of Return to Opioid Use During Immediate Community Reintegration
在立即重新融入社区期间恢复阿片类药物使用的预测
- 批准号:
10711730 - 财政年份:2018
- 资助金额:
$ 13.5万 - 项目类别:
PTSD, Negative and Positive Emotion Dysfunction and Substance USE in IPV Victims
IPV 受害者的 PTSD、消极和积极情绪功能障碍以及药物使用
- 批准号:
9476531 - 财政年份:2017
- 资助金额:
$ 13.5万 - 项目类别:
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 13.5万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 13.5万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 13.5万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 13.5万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 13.5万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 13.5万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 13.5万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 13.5万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 13.5万 - 项目类别:














{{item.name}}会员




